Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Neuroendocrine tumor Stories

2010-06-03 00:20:00

EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of Afinitor® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), is part of the largest...

2010-04-30 11:06:24

2nd European Lung Cancer Conference Fine-tuning radiotherapy to take into account which parts of a patient's tumor are growing fastest could improve control of cancer while subjecting patients to lower doses of radiation, Dutch researchers reported today at the 2nd European Lung Cancer Conference. "The only problem in radiotherapy is minimizing the side-effects," says lead researcher Dr Christian Siedschlag from the Dutch Cancer Institute. "If one could hit the tumor with arbitrarily high...

2009-12-07 19:08:23

Peptide Delivers Anti-Cancer Compounds to Where They Can Do the Most Good Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide (a chain of amino acids) that specifically recognizes and penetrates cancerous tumors but not normal tissues. The peptide was also shown to deliver diagnostic particles and medicines into the tumor. This new peptide, called iRGD, could dramatically enhance both cancer detection and treatment. The...

2009-11-23 15:51:28

In the November issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE), a study out of Stanford University found that Barrett's esophagus was detected in six percent of asymptomatic women undergoing endoscopic screening. Also in this issue, two studies examined endoscopic ultrasound (EUS): Researchers from France, in the largest single-center experience to date, demonstrated the accuracy of EUS-FNA...

2009-11-20 14:14:00

Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). PNT is a very rare form of pancreatic cancer that can stay confined to the...

2009-10-01 06:30:00

EAST HANOVER, N.J., Oct. 1 /PRNewswire/ -- Data published in the Journal of Clinical Oncology show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with Sandostatin® LAR( )Depot (octreotide acetate for injectable suspension) experienced a 66% reduction in risk of disease progression versus placebo(1). Sandostatin LAR is indicated to treat the diarrhea and flushing episodes associated with advanced carcinoid tumors(2). To view...

2009-09-17 08:34:38

UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments. The researchers refer to these microRNA collections as signatures, and their study results are reported in the September 15 issue of "Genes &...

2009-08-25 13:11:32

 Researchers from Turku, Finland, have identified a blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.Based on these findings, they suggested that the relationship between several physiological tumor parameters might provide more important information about a tumor than just looking at any of these parameters alone.Gaber...

2009-07-21 05:30:00

THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan drug designation from the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome....

2009-07-07 05:30:00

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors....